banner
 
bar
program   test   slides
bar
 
 

Critical Challenges and Landmark Advances in Osteoporosis Research

National Congress

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This course is designed for primary care physicians, family medicine specialists, bone metabolism experts, preventive medicine specialists, gynecologists, nurse practitioners, orthopedic surgeons, consulting pharmacists, internal medicine specialists, endocrinologists, women's health physicians, geriatric nurse practitioners, and rheumatologists.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheThis activity is supported by an Independent Educational Grant from Roche Laboratories Inc.

Credit Designation Statement:

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS). The UMMS is accredited by ACCME to provide continuing medical education for physicians.

The UMMS designates this continuing medical education activity for up to 2.5 credit hours in Category 1 toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Statement of Disclosure:

In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented.

Faculty Disclosures:

Clifford J. Rosen, MD
Nothing to disclose

Roberto Civitelli, MD
Grant/Research Support: Hoffman-La Roche, Procter & Gamble, Eli-Lilly, Amgen
Consultant: Roche, GSK, Merck, Amgen, Wyeth, Novartis
Speakers Bureau: Roche, Merck, Amgen, Novartis

Jonathan D. Adachi, MD, FRCP(C)
Grant/research support: Aventis, Eli Lilly and Co., GlaxoSmithKline, Merck & Co., Procter & Gamble, Novartis, NPS Allelix Corp., Roche Diagnostics, and Wyeth Pharmaceuticals;
Consultant: Amgen, AstraZeneca, Aventis, Eli Lilly and Co., GlaxoSmithKline, Merck & Co., Procter & Gamble, Novartis, and Roche Diagnostics.

Sol Epstein, MD
Grant/Research Support: Roche, Merck, NPS, Amgen
Consultant: Roche, Merck, NPS
Speakers Bureau: Roche, Merck

Stuart Silverman, MD
Grant/Research Support: Lilly, Merck, Novartis, Wyeth, P&G, Roche
Consultant: Amgen, Roche/GSK, Merck, Wyeth, Lilly, Novartis
Advisory Board: Amgen, Lilly, Merck, Novartis, P&G, Wyeth
Speakers Bureau: Lilly, Roche/GSK, Kyphon, Merck, Novartis, P&G

Mone Zaidi, MD, PhD, FRCP
Grants/research support : Procter and Gamble Pharmaceuticals, IRIS (Paris) and Genzyme Corporation
Speaker's Bureau: Alliance for Better Bone Health, Procter and Gamble and Sanofi-Aventis Pharmaceuticals, Novartis, Merck, Roche, GlaxoSmithKline

Program Chair and Faculty
Program Chairman

Clifford J. Rosen, MD
Past President, ASBMR
Clinical Professor of Nutrition
University of Maine
Director of the Maine Center for Osteoporosis
Research and Education
St. Joseph Hospital
Bangor, Maine

Distinguished Faculty:

Jonathan D. Adachi, MD, FRCP(C)
Professor, Department of Medicine
St. Joseph's Hospital
McMaster University
Hamilton, Ontario
Ontario, Canada

Roberto Civitelli, MD
Professor of Medicine, Orthopedic Surgery, and Cell Biology and Physiology
Director, Clinical Research Unit
Washington University School of Medicine
St. Louis, Missouri

Sol Epstein, MD
Professor of Medicine and Geriatrics Mount Sinai School of Medicine
Director of Osteoporosis Research and Center
Doylestown Hospital
Doylestown, Pennsylvania

Stuart Silverman, MD
Professor of Medicine
UCLA David Geffen School of Medicine
Department of Rheumatology
Los Angeles, California

Mone Zaidi, MD, PhD, FRCP
Professor of Medicine and Physiology
Director, Mount Sinai Bone Program
Mount Sinai School of Medicine
New York, New York

Educational Objectives:

Program participants will:

  • Learn how recent advances in basic and clinical research have helped to advance strategies for osteoporosis management.
  • Learn how to evaluate recent clinical trials in osteoporosis and how to apply the results of these trials to optimize management of patients with postmenopausal osteoporosis.
  • Learn to analyze concepts, strategies, and findings emanating from basic research studies in osteoporosis--at the cellular level involving ligands, osteoclastic activation, cell-cell interactions -- and determine directions for future research and trial design.
  • Learn to analyze concepts, strategies, and findings emanating from clinical research studies in osteoporosis--at the level of BMD, regimen adherence and persistence, dose and dosing frequency--and determine directions for future research and trial design, and possible implications for clinical practice.
  • Learn evidence-based approaches to reducing progression of osteoporosis, and reducing risk of fracture complications based on finding reported in the latest clinical research.
  • Learn how, based on research and evidence, to select safe and effective pharmacotherapy for prevention and treatment of postmenopausal osteoporosis.
  • Learn how landmark trials and analyses focusing on BMD, bisphosphonate therapy, predictive risk, and fracture reduction should guide clinical management of patients with osteoporosis.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar
program   test   slides
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
Osteoporosis
Bone
Bone Remodeling
Cell-Cell Interactions
Bone Marrow Microenvironment
Osteoblast Differentiation
Bisphosphonates
Bisphosphonate
Sol Epstein
Bone Strength
DXA
Bone volume
Mineralization
Trabecular connectivity
Collagen quality
microcracks,
Antifracture Efficacy
BMD



postmenopausal osteoporosis
lumbar spine
hip
nonvertebral
vertebral
Ibandronate
Bone Imaging
Alendronate
cortical porosity
cortical thickness
periosteal cells
N-Bisphosphonate Dosing
Risedronate
Zoledronic
zoledronic acid
HORIZON-PFT trial
Bone Resorption
FACT Study
MOTION Trial
FIT Baseline
Bone Microarchitecture
FLEX Study
Osteoclastogenesis
Adipogenesis
Osteoblastogenesis
osteocyte density
osteocyte apoptosis
Sclerostin
FG 23
Dentin Matrix Protein
Glococorticoid
Trabecular Thickness
Cancellous Bone
Periosteal
Endocortical
Anabolics
Teriparatide
RANKL Inhibition
Wnt
Wnt signalling pathway
Calcilytics
Roberto Civitelli
Osteoblast Differentiation
Leptin
Sclerosing
Endosteal Hyperostosis
Sclerosteosis
Van Buchem Disease
Hyperostosis
LRP-5 Mutation
Craniofacial hyperostosis
Mone Zaidi
Zaidi
MOBILE
Stuart Silverman
Silverman
i3 Innovus
annual cumulative exposure
Roche Laboratories